Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.15

€1.15

3.570%
0.04
3.570%
-
 
23.08.24 / Tradegate WKN: A3EUNZ / Name: Xortx Therapeutics Inc. / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Xortx Therapeutics Inc. Stock

Xortx Therapeutics Inc. dominated the market today, gaining €0.040 (3.570%).
For the coming years our community has positive and negative things to say abot the Xortx Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.

Pros and Cons of Xortx Therapeutics Inc. in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

News

XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders
XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders

CALGARY, AB – August 23, 2024 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on

XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024
XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024

Health consequences of over active xanthine oxidase may accelerated PKD progression

 

CALGARY, AB – August 20, 2024 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX |